Company ASLAN Pharmaceuticals Limited Taipei Exchange
Equities
6497
KYG054241099
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cancer Novel Drugs
100.0
%
| 0 | nan % | 12 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
100.0
%
| - | - | 12 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 51 | 09-12-31 | |
Director of Finance/CFO | 45 | 10-10-31 | |
Chief Tech/Sci/R&D Officer | - | 22-03-14 | |
Stephen Doyle
PRN | Corporate Officer/Principal | 50 | 18-01-31 |
Ben Goodger
LAW | General Counsel | 61 | 16-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 18-10-29 |
Chairman | 64 | 16-03-31 | |
Founder | 51 | 09-12-31 | |
Kathleen Metters
BRD | Director/Board Member | 66 | 21-03-17 |
Neil Graham
BRD | Director/Board Member | 65 | 21-02-17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 337,297,360 | 333,924,386 ( 99.00 %) | 0 | 99.00 % |
Company contact information
Aslan Pharmaceuticals Ltd.
3 Temasek Avenue 18 Level Centennial Tower
039190, Singapore
+
http://www.aslanpharma.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |